Lipella pharmaceuticals doses first two patients in phase 2a oral lichen planus clinical trial

Pittsburgh, aug. 12, 2024 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella,” “our,” “us,” “we” or the “company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces the dosing of the first two patients with lp-310 in its phase 2a clinical trial in oral lichen planus (olp) patients. lipella's phase 2a trial is a multicenter, dose-ranging study involving adult male and female subjects experiencing symptomatic oral lichen planus, a chronic inflammatory condition that affects mucous membranes in the mouth and causes burning and pain as well as white patches, swollen tissue or open sores.
LIPO Ratings Summary
LIPO Quant Ranking